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Abstract: 
Since the end of the 20th century, the development of novel approaches have emerged to manipulate 
experimental models of hematological disorders, so they would more accurately mirror what is observed in the 
clinic. Despite these technological advances, the characterization of crucial genes for benign or malignant 
hematological disorders remains challenging, mainly because of the dynamic nature of the hematopoietic 
system and the genetic heterogeneity of these disorders. To overcome this limitation, genome editing 
technologies have been developed to specifically manipulate the genome via deletion, insertion or modification 
of targeted loci. These technologies have swiftly progressed, allowing their common use to investigate genetic 
function in experimental hematology. Amongst them, homologous recombination (HR)-mediated targeting 
technologies have facilitated the manipulation of specific loci by generating knockout and knock-in models. 
Despite promoting significant advances in the understanding of the molecular mechanisms involved in 
hematology, these inefficient, time-consuming and labor-intensive approaches did not permit the development 
of cellular or animal models recapitulating the complexity of hematological disorders. In October 2016, Dr. Ben 
Ebert and Dr. Chad Cowan shared their knowledge and experiences with the utilization of CRISPR for models 
of myeloid malignancy, disease, and novel therapeutics. Here we provide an overview of the topics they 
covered including insights into the novel applications of the technique as well as its strengths and limitations.  
 
Introduction: 
Over the past decade, novel genome-editing approaches targeting DNA double-stranded breaks 
(DSBs) were developed to stimulate DNA repair pathways, namely non-homologous end-joining (NHEJ) and 
site-specific HR. The introduction of DSB stimulates the recruitment of the HR machinery at a specific loci. This 
crucial process involves different targeted nucleases with distinguishing characteristics, such as DNA 
recognition and endonucleic DNA cleavage capacities. The discovery these targeted nucleases and the 
subsequent development of engineered nucleases, such as zinc-finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and Clustered Regularly Interspaced Short Palindrome Repeats 
and their associated Cas proteins (CRISPR/Cas9), has enabled the development of novel site-specific gene 
editing technologies (1). However, these technologies generated random insertions or deletions (indels) 
following the stimulation of error-prone NHEJ in most cases, leading to frameshift mutations. When available, 
the use of an exogenous donor DNA template surrounding the site-specific DSBs allowed to bypass this 
significant hurdle by involving high-fidelity HR-mediated repair. Although ZFNs and TALENs have significantly 
improved our capacity to perform site-specific genome editing, their widespread application in hematology has 
been restricted by elaborate procedures, high cost and low specificity. On the other hand, the noticeable 
efficiency of the CRISPR/Cas9 system offers the greatest flexibility for genome editing by overcoming the 
limitations of earlier targeted nuclease-mediated methods. 
In that regards, the development of the CRISPR/Cas9 system may represent a milestone for medical research 
as it allows researchers to effectively develop complex experimental models of benign and malignant 
hematological disorders. Here we highlight the implications of this powerful system by summarizing the ISEH 
webinar presented on October 26th, 2016 by Benjamin Ebert and Chad Cowan, entitled “Utility of 
CRISPR/Cas9 systems in hematology research”, which was moderated by Eirini Papapetrou (2). 
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Dr Benjamin Ebert: CRISPR models of myeloid malignancy 
 
Dr. Benjamin Ebert presented recent work from his lab where they have used CRISPR/Cas9 
technology to model myeloid malignancies in vivo. Most myelodyplastic syndrome (MDS)/ acute myeloid 
leukemia (AML) patients have, on average, three to five mutations that contribute to disease progression (3). 
Further, these mutations are not uniformly distributed through the hematopoietic cells of the patient. It is now 
clear that initiating mutations cause the expansion of preleukemic clones that then acquire additional mutations 
that lead MDS and ultimately AML. Leukemic and preleukemic clones with different mutations coexist in vivo 
and chemotherapy might eliminate some clones without affecting others. Modeling these complex behaviors 
using transgenic mouse models is thus not feasible. The Ebert research group has recognized that there is a 
need for better models that reflect the genetic complexity and cellular heterogeneity observed in cancer 
patients.  The ideal model should target hematopoietic stem and progenitor cells (HSPCs), work in vivo, and 
mimic the genetic complexity of human disease. The model should also be easily customizable and serially 
transplantable and amenable to pharmacological testing. To accomplish this the Ebert laboratory has used 
CRISPR/Cas9 to model MDS/AML in murine and human HSPCs. Their approach is to use CRISPR/Cas9 to 
introduce insertions or deletions in multiple alleles in a single HSPC. For achieving this, they co-infected 
HSPCs with a lentiviral vector carrying a single RNA guide, the Cas9 cDNA and an eGFP reporter 
concomitantly with multiple vectors each expressing a single RNA guide and a red fluorescent protein (RFP) 
reporter (4). Using this strategy they were able to simultaneously, and biallelically, inactivate Dnmt3a, Ezh2, 
Smc4 and Nf1 (eight different alleles) in a single HSPC leading to leukemia after transplantation in mice (4). 
The Ebert group has also used CRISPR/Cas9 to model genetic progression in mice by starting with Tet2-/- 
HSPCs, followed by the introduction of secondary mutations in six different alleles. They subsequently 
assessed the effect of these mutations in a primary transplant, from which mutated HSPCs were harvested 
and two additional mutations were introduced for testing in secondary transplants. These experiments confirm 
the feasibility of using CRISPR/Cas9 to rapidly model multiple mutations and leukemic progression in a much 
faster fashion than using conventional gene targeting and breeding strategies in mice. The other significant 
advantage is that CRISPR/Cas9 can also be used in human HSPCs. The Ebert research group has used these 
engineered human HSPCs carrying mutations that were predicted to confer sensitivity to hypomethylating 
agents (e.g in the Tet2 locus) and demonstrated that these mutant HSPCs are more vulnerable to azacitidine 
in vivo (5). These experiments indicate that these engineered HSPCs can be used to test new drugs for 
complex hematological malignancies. 
 
Dr Chad Cowan: Genome editing – from modeling disease to novel therapeutics 
 
Dr. Chad Cowan discussed the use of CRISPR/Cas9 for genome editing to create novel disease/animal 
models and for potential therapeutic use to bridge biological discovery to clinical therapy. Initial comparison 
studies of genome editing via CRISPR/Cas9 (an RNA guided endonuclease) versus the use of TALENs (DNA 
binding motif based endonuclease) showed that CRISPR/Cas9 had higher overall efficiency (50-80%), as well 
as an increase in homozygous knock outs and knock in detection, and no off target events where the TALENs 
had 0-30% efficiency, diminished knock out and knock in potential, and 1 on target translocation detected (6-8). 
Therefore, his group uses the CRISPR/Cas9 system because it allows them to efficiently create clinically 
relevant, pluripotent, isogenic models (that can be differentiated into hepatocytes or other cells of interest) with 
side by side mutational analysis without the need for patient recruitment or quality control of multiple induced 
pluripotent stem cell (iPS) lines. Dr. Cowan’s group has utilized these models for high throughput screens to 
detect genes associated with lipid metabolism (such as A1CF) as well as for investigations of the therapeutic 
potential of CRISPR in the context of HIV. To investigate the therapeutic potential the CRISPR/Cas9 system, 
they engineered a novel doubled guided approach to enhance efficiency of the CCR5 (the co-receptor for HIV) 
knockout in CD34+ HSPCs from mobilized peripheral blood. This strategy resulted in homozygous bi-allelic 
editing (40-50% efficiency) with no change in the in vitro or in vivo multi-lineage potential of the cells. To 
confirm the safety of this strategy Target Capture Sequencing was done to allow for very deep sequencing at 
specific sites, especially those that are similar to the guide RNA, as these sites are most likely to have 
mutations in the CRISPR/Cas9 system. Only 1 statistically significant mutation was detected, which could have 
been eliminated with utilization of different software, highlighting that good guide design is absolutely critical 
when using the CRISPR/Cas9 system. Overall, the Cowan laboratory has shown that CRISPR/Cas9 system 
enables the creation of clinically relevant disease models (utilizing cell types that have classically had low rates 
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of efficiency) with very low occurrence off target mutations making it an extremely useful tool for biological 
discovery and potentially clinical therapeutics.  
 
Summary 
 
Altogether, these studies describe the few of the possible applications of the CRISPR/Cas9 system to 
effectively develop complex experimental models of benign and malignant hematological disorders. As such, 
this powerful tool may represent a milestone for medical research as it renders possible to model more 
accurately complex multigenic and heterogeneous diseases. The research programs led by Dr. Ebert and Dr. 
Cowan brilliantly highlight a few of the various possibilities that offer the CRISPR/Cas9 system, such as the 
development of cell-based clinically relevant drug screens for complex hematological malignancies. The 
CRISPR/Cas9 system has already triggered a technical revolution in medical research, and we can expect that 
its wonderful possibilities will soon be translated into the clinic.   
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Highlights for Utility of CRISPR/Cas9 systems in hematology research: 
o CRISPR/Cas9 overcomes limitations of earlier targeted nuclease-mediated 
methods. 
 
o CRISPR/Cas9 allows for insertions/deletions in multiple alleles in a single HSPC. 
 
 
o Genome editing provides models to bridge biological discovery to clinical 
therapy. 
 
o CRISPR/Cas9 allows for generation of isogenic models with mutational analysis. 
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